Genmab AS - Company Profile
Powered by
All the data and insights you need on Genmab AS in one report.
- Save hours of research time and resources with
our up-to-date Genmab AS Strategy Report
- Understand Genmab AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Genmab AS Catalyst Calendar
Proactively evaluate Genmab AS’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Genmab AS Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
30 Sep 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
29 Sep 2019 | Phase I/II Trial Results | Belgian Gynaecological Oncology Group; Genmab AS; GOG Foundation Inc; Merck & Co Inc; Seagen Inc; The European Network of Gynaecological Oncological Trial Groups | GMAB; MRK; SGEN | pembrolizumab; tisotumab vedotin | Oncology | Cervical Cancer | Company Press Release |
08 Sep 2019 | Phase I/II Trial Results | Genmab AS | GMAB | enapotamab vedotin | Oncology | Anaplastic Thyroid Cancer; Cervical Cancer; Endometrial Cancer; Melanoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Sarcomas; Solid Tumor; Thyroid Cancer | Company Press Release |
01 Sep 2019 | Phase III Trial Completion | Genmab AS; Novartis AG | GMAB; NOVN | Kesimpta | Central Nervous System | Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS); Relapsing Remitting Multiple Sclerosis (RRMS); Secondary Progressive Multiple Sclerosis (SPMS) | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer